DGAP-News: Balda AG / Key word(s): Half Year Results
Balda records positive revenue and operating result trend in the first
11.02.2015 / 07:30
– Revenue up by EUR 5.5 million to EUR 40.4 million
– EBITDA (EUR 2.7 million) and EBIT (EUR 0.4 million) continue positive
trend as expected
– CEO Oliver Oechsle: “significant step closer to operational turnaround”
– Revenue forecast for 2014 / 2015 financial year again confirmed:
revenue at the top end of the EUR 73 to 78 million range with positive
Bad Oeynhausen, 11 February 2015 – Balda AG posted consolidated revenue of
EUR 40.4 million in the first half-year 2014 / 2015 compared to EUR 34.9
million in the equivalent period of the previous year. Higher sales in
healthcare products in the Europe segment primarily contributed to this
“The significant increase in demand for healthcare products indicates that
our more intensive activities are paying off. We are closer to the market
and our customers appreciate our product quality and dependability,”
remarked Oliver Oechsle, CEO of Balda AG, adding: “This confirms that we
have adopted the right approach and that Balda is back on track.”
Key revenue and earnings figures for the Balda Group in the first half-year
After generating total revenue of EUR 20.7 million in the first quarter,
the positive trend continued in the second with the figure coming in at
EUR 19.7 million. This means the Balda Group achieved total revenue of EUR
40.4 million in the period under review compared with EUR 34.9 million in
the equivalent period of the previous year. This represents a 15.8 %
increase. As in the first three months, Balda reported significantly
stronger demand for med-tech products.
In the period from July to December 2014, Balda AG posted earnings before
interest, tax, depreciation and amortization (EBITDA) of EUR 2.7 million
compared to EUR 1.1 million in the prior-year period, which represents an
EBITDA margin of 6.8 %. At operational level, the Group reported earnings
before interest and taxes (EBIT) of EUR 0.4 million after EBIT came in at a
loss of EUR -1.5 million in the equivalent period of the previous year. The
EBIT margin in the first half-year of the financial year 2014 / 2015
therefore stood at 1.0 %.
At EUR 3.7 million, the company’s consolidated earnings after taxes were
significantly below the previous year’s figure of EUR 11.1 million, which
is attributable to a lower financial result due to weaker currency results.
“After the first half-year 2014/2015, our figures prove that we have taken
a significant step towards our goal of achieving an operational turnaround.
We will continue to work intensively on making Balda even stronger and more
profitable,” indicated CEO Oliver Oechsle.
Operating segments performance
The America segment posted growth of 7.7 % in the reporting period with
revenue recorded at EUR 21.6 million (previous year: EUR 20.1 million).
However, at EUR 1.7 million the segment’s EBITDA was considerably higher
than the previous year’s figure of EUR 1.2 million. The segment’s EBIT was
positive in the period under review after EUR -0.3 million in the previous
year and climbed to EUR 0.3 million.
In the Europe segment, Balda achieved a substantial 26.7 % increase in
revenue to EUR 18.8 million after generating EUR 14.9 million in the
prior-year period. This significant rise is primarily attributable to the
stronger demand for healthcare products. Both the segment’s EBITDA and EBIT
were well in the black in the first half-year 2014 / 2015 after losses in
the equivalent period of the previous year. EBITDA rose from EUR -0.06
million to EUR 1.2 million while EBIT came in at EUR 0.3 million after
EUR -1.2 million in the previous year.
In the Other segment, general holding company costs once again resulted in
a slight EBITDA loss of EUR -0.2 million in the period under review after
EUR -0.06 million in the prior-year period.
Balda AG’s Management Board reconfirmed its forecast for the current 2014 /
2015 financial year. The forecast applies provided the macroeconomic
conditions do not deteriorate significantly and no other unforeseeable
negative events of major consequence to the Balda Group occur. The company
is targeting consolidated revenue of EUR 73 million to EUR 78 million, but
now expects the figure to come in at the upper end of the forecast range.
The Management Board is also aiming for positive earnings before interest
and taxes (EBIT) and an EBIT margin in the low single-digit percentage
The latest half-year report 2014 / 2015 can be downloaded from the investor
relations section of Balda’s website.
Deekeling Arndt Advisors
Phone: +49 (0) 5734 922 2555
Mobile: +49 (0) 160 90560506
Balda (ISIN: DE0005215107) is a provider of first-class solutions in
plastics for demanding, high-quality applications in the fields of
healthcare, lifestyle, automotive and consumer electronics industries.
Balda has operating divisions in Europe and America and maintains
state-of-the-art production facilities at its headquarter in Bad
Oeynhausen, Germany as well as in the USA. The success of Balda, which
employs around 770 people, is based on the deployment of leading-edge,
cost-effective technologies, coupled with the trust-based and close
collaboration with customers.
11.02.2015 Dissemination of a Corporate News, transmitted by DGAP – a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Company: Balda AG
Bergkirchener Str. 228
32549 Bad Oeynhausen
Phone: +49 (0) 57 34 / 9 22-0
Fax: +49 (0) 57 34 / 9 22-2604
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
End of News DGAP News-Service